BACKGROUND: Mutations or single nucleotide polymorphism (SNP) of relevant genes may affect the risk and prognosis of malignancies. The purpose of this study was to analyze whether the KRAS polymorphisms and mutations can be useful prognostic or risk markers in oral squamous cell carcinoma (OSCC). METHODS: DNA was extracted from tumor tissues of 47 patients with OSCC and blood cells of 84 normal controls and subjected to sequencing for the KRAS. RESULTS: No mutation in the KRAS was found in 47 OSCC samples. However, 2 polymorphisms (rs1137282 and rs712) were detected. Individuals with KRAS SNP rs712 genotypes of G/T or T/T have a reduced risk for OSCC than those with genotype G/G (hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.10-0.60; p = .004). The overall survival between different SNPs were not statistically significant (p = .147 for rs1137282 and p = .202 for rs712). CONCLUSION: These data demonstrate a role for rs712 polymorphism of the KRAS in susceptibility of OSCC.
BACKGROUND: Mutations or single nucleotide polymorphism (SNP) of relevant genes may affect the risk and prognosis of malignancies. The purpose of this study was to analyze whether the KRAS polymorphisms and mutations can be useful prognostic or risk markers in oral squamous cell carcinoma (OSCC). METHODS: DNA was extracted from tumor tissues of 47 patients with OSCC and blood cells of 84 normal controls and subjected to sequencing for the KRAS. RESULTS: No mutation in the KRAS was found in 47 OSCC samples. However, 2 polymorphisms (rs1137282 and rs712) were detected. Individuals with KRAS SNP rs712 genotypes of G/T or T/T have a reduced risk for OSCC than those with genotype G/G (hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.10-0.60; p = .004). The overall survival between different SNPs were not statistically significant (p = .147 for rs1137282 and p = .202 for rs712). CONCLUSION: These data demonstrate a role for rs712 polymorphism of the KRAS in susceptibility of OSCC.
Authors: I Sullivan; J Salazar; C Arqueros; M Andrés; A Sebio; M Majem; J Szafranska; E Martínez; D Páez; A López-Pousa; M Baiget; A Barnadas Journal: Clin Transl Oncol Date: 2017-02-01 Impact factor: 3.405